25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

8EM (Editas Medicine Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Editas Medicine Inc together

I guess you are interested in Editas Medicine Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Editas Medicine Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Editas Medicine Inc’s Price Targets

I'm going to help you getting a better view of Editas Medicine Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Editas Medicine Inc

I send you an email if I find something interesting about Editas Medicine Inc.

1. Quick Overview

1.1. Quick analysis of Editas Medicine Inc (30 sec.)










1.2. What can you expect buying and holding a share of Editas Medicine Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.64
Expected worth in 1 year
€-1.73
How sure are you?
26.1%

+ What do you gain per year?

Total Gains per Share
€-2.37
Return On Investment
-95.0%

For what price can you sell your share?

Current Price per Share
€2.50
Expected price per share
€1.4065 - €3.364
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Editas Medicine Inc (5 min.)




Live pricePrice per Share (EOD)
€2.50
Intrinsic Value Per Share
€-11.99 - €-13.64
Total Value Per Share
€-11.35 - €-13.00

2.2. Growth of Editas Medicine Inc (5 min.)




Is Editas Medicine Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$62.4m$350.9m-$199.8m-132.3%

How much money is Editas Medicine Inc making?

Current yearPrevious yearGrowGrow %
Making money-$62.8m-$41.5m-$21.2m-33.9%
Net Profit Margin-29,207.8%-1,932.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Editas Medicine Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#392 / 872

Most Revenue
#299 / 872

Most Profit
#805 / 872

Most Efficient
#851 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Editas Medicine Inc?

Welcome investor! Editas Medicine Inc's management wants to use your money to grow the business. In return you get a share of Editas Medicine Inc.

First you should know what it really means to hold a share of Editas Medicine Inc. And how you can make/lose money.

Speculation

The Price per Share of Editas Medicine Inc is €2.496. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Editas Medicine Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Editas Medicine Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.64. Based on the TTM, the Book Value Change Per Share is €-0.59 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Editas Medicine Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-0.91-36.4%-0.75-30.1%-0.50-19.9%-0.62-25.0%-0.57-22.7%-0.55-22.0%
Usd Book Value Change Per Share-0.86-34.4%-0.69-27.8%-0.07-2.8%-0.45-18.0%-0.10-4.1%0.031.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.86-34.4%-0.69-27.8%-0.07-2.8%-0.45-18.0%-0.10-4.1%0.031.3%
Usd Price Per Share1.28-2.85-8.87-7.70-20.62-21.28-
Price to Earnings Ratio-0.35--0.95--5.73--3.73--5.06--6.34-
Price-to-Total Gains Ratio-1.49--4.12--25.00--16.21--28.02--24.48-
Price to Book Ratio1.72-1.54-2.13-2.03-3.90-4.57-
Price-to-Total Gains Ratio-1.49--4.12--25.00--16.21--28.02--24.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.9183232
Number of shares342
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.69-0.10
Usd Total Gains Per Share-0.69-0.10
Gains per Quarter (342 shares)-236.94-35.16
Gains per Year (342 shares)-947.75-140.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-948-9580-141-151
20-1895-19060-281-292
30-2843-28540-422-433
40-3791-38020-563-574
50-4739-47500-703-715
60-5686-56980-844-856
70-6634-66460-985-997
80-7582-75940-1125-1138
90-8530-85420-1266-1279
100-9477-94900-1407-1420

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.022.00.04.3%1.022.00.04.3%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%6.017.00.026.1%6.017.00.026.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.023.00.0%0.00.023.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%6.017.00.026.1%6.017.00.026.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Editas Medicine Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.734-0.593-19%-0.059-92%-0.383-48%-0.088-88%0.028-2748%
Book Value Per Share--0.6381.544-59%3.586-82%3.037-79%3.950-84%3.749-83%
Current Ratio--3.0753.606-15%6.049-49%6.082-49%7.659-60%7.486-59%
Debt To Asset Ratio--0.7630.558+37%0.295+159%0.370+106%0.314+143%0.335+128%
Debt To Equity Ratio--3.2241.573+105%0.420+667%0.782+312%0.592+444%0.633+410%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---80280682.68851189482.904-257%510676910.125-116%421229838.036-119%1346434750.969-106%1386704727.535-106%
Eps---0.777-0.642-17%-0.424-45%-0.534-31%-0.485-38%-0.470-40%
Ev To Sales Ratio---5.038182.599-103%48.053-110%634.504-101%554.425-101%492.383-101%
Free Cash Flow Per Share---0.490-0.550+12%-0.386-21%-0.455-7%-0.454-7%-0.459-6%
Free Cash Flow To Equity Per Share---0.504-0.411-18%-0.084-83%-0.207-59%-0.048-91%-0.071-86%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---13.642----------
Intrinsic Value_10Y_min---11.986----------
Intrinsic Value_1Y_max---1.755----------
Intrinsic Value_1Y_min---1.725----------
Intrinsic Value_3Y_max---4.978----------
Intrinsic Value_3Y_min---4.759----------
Intrinsic Value_5Y_max---7.844----------
Intrinsic Value_5Y_min---7.307----------
Market Cap208947388.416+56%91833046.912203704868.304-55%635171598.400-86%551483118.661-83%1476458996.509-94%1523605644.575-94%
Net Profit Margin---16.335-292.078+1688%-19.322+18%-216.257+1224%-138.712+749%-121.411+643%
Operating Margin----0%-2.3500%-116.4300%-78.8900%-69.4120%
Operating Ratio--8.581307.339-97%22.024-61%226.198-96%145.151-94%127.233-93%
Pb Ratio3.914+56%1.7201.535+12%2.134-19%2.028-15%3.896-56%4.574-62%
Pe Ratio-0.803-128%-0.353-0.946+168%-5.729+1524%-3.734+958%-5.064+1336%-6.345+1698%
Price Per Share2.496+56%1.0972.433-55%7.588-86%6.588-83%17.637-94%18.200-94%
Price To Free Cash Flow Ratio-1.275-128%-0.560-1.062+90%-5.520+885%-4.082+629%-10.289+1737%-9.287+1558%
Price To Total Gains Ratio-3.400-128%-1.494-4.125+176%-25.000+1573%-16.205+984%-28.022+1775%-24.482+1538%
Quick Ratio--1.1322.092-46%3.812-70%3.594-68%4.079-72%3.972-71%
Return On Assets---0.289-0.197-32%-0.086-70%-0.129-55%-0.101-65%-0.099-66%
Return On Equity---1.219-0.551-55%-0.123-90%-0.272-78%-0.194-84%-0.189-85%
Total Gains Per Share---0.734-0.593-19%-0.059-92%-0.383-48%-0.088-88%0.028-2748%
Usd Book Value--62421046.159151086782.172-59%350974882.240-82%297215397.913-79%386635879.909-84%366944497.713-83%
Usd Book Value Change Per Share---0.858-0.693-19%-0.069-92%-0.448-48%-0.103-88%0.032-2748%
Usd Book Value Per Share--0.7461.805-59%4.193-82%3.550-79%4.619-84%4.383-83%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---93864174.19959850743.411-257%597083443.318-116%492501926.632-119%1574251510.833-106%1621335167.434-106%
Usd Eps---0.909-0.750-17%-0.496-45%-0.625-31%-0.567-38%-0.549-40%
Usd Free Cash Flow---47913803.022-53820902.023+12%-37758632.824-21%-44493412.364-7%-44397444.089-7%-41051644.536-14%
Usd Free Cash Flow Per Share---0.572-0.643+12%-0.451-21%-0.532-7%-0.530-7%-0.537-6%
Usd Free Cash Flow To Equity Per Share---0.590-0.480-18%-0.098-83%-0.242-59%-0.056-91%-0.083-86%
Usd Market Cap244301286.536+56%107371198.450238171732.021-55%742642632.849-86%644794062.339-83%1726275858.718-94%1781399719.637-94%
Usd Price Per Share2.918+56%1.2832.845-55%8.871-86%7.702-83%20.621-94%21.280-94%
Usd Profit---76089275.235-62808802.658-17%-41533946.097-45%-53027305.389-30%-47880102.457-37%-46349515.935-39%
Usd Revenue--4658078.0688959150.153-48%17352040.815-73%10669678.821-56%12268105.610-62%11618151.239-60%
Usd Total Gains Per Share---0.858-0.693-19%-0.069-92%-0.448-48%-0.103-88%0.032-2748%
 EOD+5 -3MRQTTM+7 -28YOY+5 -303Y+5 -305Y+5 -3010Y+5 -30

3.3 Fundamental Score

Let's check the fundamental score of Editas Medicine Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.803
Price to Book Ratio (EOD)Between0-13.914
Net Profit Margin (MRQ)Greater than0-16.335
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.132
Current Ratio (MRQ)Greater than13.075
Debt to Asset Ratio (MRQ)Less than10.763
Debt to Equity Ratio (MRQ)Less than13.224
Return on Equity (MRQ)Greater than0.15-1.219
Return on Assets (MRQ)Greater than0.05-0.289
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Editas Medicine Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.544
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-07-06 03:06:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Editas Medicine Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Editas Medicine Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -1,633.5%Β means thatΒ €-16.33 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Editas Medicine Inc:

  • The MRQ is -1,633.5%. The company is making a huge loss. -2
  • The TTM is -29,207.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,633.5%TTM-29,207.8%+27,574.3%
TTM-29,207.8%YOY-1,932.2%-27,275.6%
TTM-29,207.8%5Y-13,871.2%-15,336.6%
5Y-13,871.2%10Y-12,141.1%-1,730.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,633.5%-93.6%-1,539.9%
TTM-29,207.8%-140.9%-29,066.9%
YOY-1,932.2%-197.6%-1,734.6%
3Y-21,625.7%-248.5%-21,377.2%
5Y-13,871.2%-343.4%-13,527.8%
10Y-12,141.1%-496.2%-11,644.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Editas Medicine Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Editas Medicine Inc to theΒ Biotechnology industry mean.
  • -28.9% Return on Assets means thatΒ Editas Medicine Inc generatedΒ €-0.29 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Editas Medicine Inc:

  • The MRQ is -28.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.9%TTM-19.7%-9.2%
TTM-19.7%YOY-8.6%-11.1%
TTM-19.7%5Y-10.1%-9.6%
5Y-10.1%10Y-9.9%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.9%-11.6%-17.3%
TTM-19.7%-11.6%-8.1%
YOY-8.6%-11.4%+2.8%
3Y-12.9%-11.8%-1.1%
5Y-10.1%-12.0%+1.9%
10Y-9.9%-13.7%+3.8%
4.3.1.3. Return on Equity

Shows how efficient Editas Medicine Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Editas Medicine Inc to theΒ Biotechnology industry mean.
  • -121.9% Return on Equity means Editas Medicine Inc generated €-1.22Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Editas Medicine Inc:

  • The MRQ is -121.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -55.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-121.9%TTM-55.1%-66.8%
TTM-55.1%YOY-12.3%-42.8%
TTM-55.1%5Y-19.4%-35.7%
5Y-19.4%10Y-18.9%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-121.9%-13.5%-108.4%
TTM-55.1%-14.9%-40.2%
YOY-12.3%-14.6%+2.3%
3Y-27.2%-16.8%-10.4%
5Y-19.4%-17.5%-1.9%
10Y-18.9%-19.9%+1.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Editas Medicine Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Editas Medicine Inc is operatingΒ .

  • Measures how much profit Editas Medicine Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Editas Medicine Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Editas Medicine Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-235.0%+235.0%
TTM-5Y-7,889.0%+7,889.0%
5Y-7,889.0%10Y-6,941.2%-947.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--232.5%+232.5%
TTM--250.5%+250.5%
YOY-235.0%-209.2%-25.8%
3Y-11,643.0%-234.1%-11,408.9%
5Y-7,889.0%-346.1%-7,542.9%
10Y-6,941.2%-477.5%-6,463.7%
4.3.2.2. Operating Ratio

Measures how efficient Editas Medicine Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 8.58 means that the operating costs are €8.58 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Editas Medicine Inc:

  • The MRQ is 8.581. The company is inefficient in keeping operating costs low. -1
  • The TTM is 307.339. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ8.581TTM307.339-298.759
TTM307.339YOY22.024+285.315
TTM307.3395Y145.151+162.188
5Y145.15110Y127.233+17.918
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.5812.111+6.470
TTM307.3392.694+304.645
YOY22.0243.096+18.928
3Y226.1983.652+222.546
5Y145.1514.745+140.406
10Y127.2336.614+120.619
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Editas Medicine Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Editas Medicine Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.08Β means the company has €3.08 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Editas Medicine Inc:

  • The MRQ is 3.075. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.606. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.075TTM3.606-0.530
TTM3.606YOY6.049-2.443
TTM3.6065Y7.659-4.054
5Y7.65910Y7.486+0.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0753.661-0.586
TTM3.6063.846-0.240
YOY6.0494.140+1.909
3Y6.0824.688+1.394
5Y7.6595.746+1.913
10Y7.4866.147+1.339
4.4.3.2. Quick Ratio

Measures if Editas Medicine Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Editas Medicine Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 1.13Β means the company can pay off €1.13 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Editas Medicine Inc:

  • The MRQ is 1.132. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 2.092. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.132TTM2.092-0.960
TTM2.092YOY3.812-1.720
TTM2.0925Y4.079-1.987
5Y4.07910Y3.972+0.107
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1322.848-1.716
TTM2.0923.169-1.077
YOY3.8123.786+0.026
3Y3.5944.311-0.717
5Y4.0795.703-1.624
10Y3.9726.368-2.396
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Editas Medicine Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Editas Medicine IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Editas Medicine Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.76Β means that Editas Medicine Inc assets areΒ financed with 76.3% credit (debt) and the remaining percentage (100% - 76.3%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Editas Medicine Inc:

  • The MRQ is 0.763. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.558. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.763TTM0.558+0.205
TTM0.558YOY0.295+0.263
TTM0.5585Y0.314+0.244
5Y0.31410Y0.335-0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7630.329+0.434
TTM0.5580.349+0.209
YOY0.2950.331-0.036
3Y0.3700.340+0.030
5Y0.3140.349-0.035
10Y0.3350.379-0.044
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Editas Medicine Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Editas Medicine Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 322.4% means that company has €3.22 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Editas Medicine Inc:

  • The MRQ is 3.224. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.573. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ3.224TTM1.573+1.651
TTM1.573YOY0.420+1.153
TTM1.5735Y0.592+0.980
5Y0.59210Y0.633-0.040
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2240.379+2.845
TTM1.5730.437+1.136
YOY0.4200.414+0.006
3Y0.7820.450+0.332
5Y0.5920.464+0.128
10Y0.6330.515+0.118
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Editas Medicine Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Editas Medicine Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -0.35 means the investor is paying €-0.35Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Editas Medicine Inc:

  • The EOD is -0.803. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.353. Based on the earnings, the company is expensive. -2
  • The TTM is -0.946. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.803MRQ-0.353-0.450
MRQ-0.353TTM-0.946+0.594
TTM-0.946YOY-5.729+4.783
TTM-0.9465Y-5.064+4.118
5Y-5.06410Y-6.345+1.280
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.803-2.356+1.553
MRQ-0.353-2.077+1.724
TTM-0.946-2.574+1.628
YOY-5.729-3.760-1.969
3Y-3.734-3.773+0.039
5Y-5.064-6.193+1.129
10Y-6.345-6.876+0.531
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Editas Medicine Inc:

  • The EOD is -1.275. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.560. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.062. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.275MRQ-0.560-0.714
MRQ-0.560TTM-1.062+0.502
TTM-1.062YOY-5.520+4.458
TTM-1.0625Y-10.289+9.227
5Y-10.28910Y-9.287-1.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.275-3.246+1.971
MRQ-0.560-2.705+2.145
TTM-1.062-3.704+2.642
YOY-5.520-4.402-1.118
3Y-4.082-5.070+0.988
5Y-10.289-8.477-1.812
10Y-9.287-9.305+0.018
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Editas Medicine Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.72 means the investor is paying €1.72Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Editas Medicine Inc:

  • The EOD is 3.914. Based on the equity, the company is fair priced.
  • The MRQ is 1.720. Based on the equity, the company is underpriced. +1
  • The TTM is 1.535. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.914MRQ1.720+2.194
MRQ1.720TTM1.535+0.185
TTM1.535YOY2.134-0.599
TTM1.5355Y3.896-2.361
5Y3.89610Y4.574-0.678
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.9142.038+1.876
MRQ1.7201.843-0.123
TTM1.5352.125-0.590
YOY2.1342.442-0.308
3Y2.0282.492-0.464
5Y3.8963.652+0.244
10Y4.5744.311+0.263
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets263,652
Total Liabilities201,232
Total Stockholder Equity62,420
 As reported
Total Liabilities 201,232
Total Stockholder Equity+ 62,420
Total Assets = 263,652

Assets

Total Assets263,652
Total Current Assets224,843
Long-term Assets38,809
Total Current Assets
Cash And Cash Equivalents 138,692
Short-term Investments 82,272
Net Receivables 510
Other Current Assets 3,369
Total Current Assets  (as reported)224,843
Total Current Assets  (calculated)224,843
+/-0
Long-term Assets
Property Plant Equipment 34,611
Long-term Assets Other 4,198
Long-term Assets  (as reported)38,809
Long-term Assets  (calculated)38,809
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities73,114
Long-term Liabilities128,118
Total Stockholder Equity62,420
Total Current Liabilities
Accounts payable 5,465
Total Current Liabilities  (as reported)73,114
Total Current Liabilities  (calculated)5,465
+/- 67,649
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt31,133
Long-term Liabilities Other 6,363
Long-term Liabilities  (as reported)128,118
Long-term Liabilities  (calculated)37,496
+/- 90,622
Total Stockholder Equity
Total Stockholder Equity (as reported)62,420
Total Stockholder Equity (calculated)0
+/- 62,420
Other
Capital Stock8
Common Stock Shares Outstanding 83,710
Net Invested Capital 62,420
Net Working Capital 151,729
Property Plant and Equipment Gross 62,279



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
372,359
508,885
466,737
655,481
597,157
572,602
780,294
755,880
717,019
677,483
623,108
580,833
531,029
514,321
464,105
541,953
504,650
499,153
440,347
384,801
327,567
341,589
263,652
263,652341,589327,567384,801440,347499,153504,650541,953464,105514,321531,029580,833623,108677,483717,019755,880780,294572,602597,157655,481466,737508,885372,359
   > Total Current Assets 
339,211
463,844
425,106
610,126
506,827
419,087
632,316
616,292
567,608
507,310
497,031
461,377
426,629
356,754
324,458
440,978
358,603
340,829
305,555
286,354
271,139
289,315
224,843
224,843289,315271,139286,354305,555340,829358,603440,978324,458356,754426,629461,377497,031507,310567,608616,292632,316419,087506,827610,126425,106463,844339,211
       Cash And Cash Equivalents 
104,772
238,183
232,850
485,819
279,576
139,682
354,918
337,834
259,884
203,519
210,881
169,401
210,704
141,522
129,021
220,817
82,537
123,652
69,227
64,441
95,832
131,541
138,692
138,692131,54195,83264,44169,227123,65282,537220,817129,021141,522210,704169,401210,881203,519259,884337,834354,918139,682279,576485,819232,850238,183104,772
       Short-term Investments 
227,844
218,957
182,143
112,901
215,729
262,428
270,415
272,719
297,957
296,326
277,481
283,157
208,913
202,752
189,418
211,151
267,080
199,459
226,944
214,671
169,256
138,372
82,272
82,272138,372169,256214,671226,944199,459267,080211,151189,418202,752208,913283,157277,481296,326297,957272,719270,415262,428215,729112,901182,143218,957227,844
       Net Receivables 
311
2,218
1,832
1,865
1,055
6,048
672
331
251
267
1,371
713
120
5,145
242
2,286
2,422
10,187
245
244
126
16,266
510
51016,26612624424510,1872,4222,2862425,1451207131,3712672513316726,0481,0551,8651,8322,218311
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
7,298
8,106
6,892
7,335
5,777
6,724
6,564
7,531
9,139
6,998
5,925
3,136
3,369
3,3693,1365,9256,9989,1397,5316,5646,7245,7777,3356,8928,1067,2980000000000
   > Long-term Assets 
33,148
45,041
41,631
45,355
90,330
153,515
147,978
139,588
149,411
170,173
126,077
119,456
104,400
157,567
139,647
100,975
58,236
158,324
134,792
98,447
56,428
52,274
38,809
38,80952,27456,42898,447134,792158,32458,236100,975139,647157,567104,400119,456126,077170,173149,411139,588147,978153,51590,33045,35541,63145,04133,148
       Property Plant Equipment 
27,756
39,648
39,240
41,464
40,467
39,148
43,400
45,224
43,432
43,291
40,715
36,864
38,026
59,217
49,555
47,657
43,495
45,712
44,700
51,107
51,147
47,051
34,611
34,61147,05151,14751,10744,70045,71243,49547,65749,55559,21738,02636,86440,71543,29143,43245,22443,40039,14840,46741,46439,24039,64827,756
       Long Term Investments 
0
0
0
0
45,986
109,664
97,890
87,584
99,198
120,071
78,046
75,062
58,844
93,097
83,339
48,065
96,797
104,024
80,605
39,195
0
0
0
00039,19580,605104,02496,79748,06583,33993,09758,84475,06278,046120,07199,19887,58497,890109,66445,9860000
       Long-term Assets Other 
5,392
5,393
2,391
3,891
3,877
4,703
6,688
6,780
6,781
6,811
7,316
7,530
7,530
5,253
6,753
5,253
5,755
8,588
9,487
8,145
5,281
5,223
4,198
4,1985,2235,2818,1459,4878,5885,7555,2536,7535,2537,5307,5307,3166,8116,7816,7806,6884,7033,8773,8912,3915,3935,392
> Total Liabilities 
162,369
246,448
232,170
228,709
156,005
179,016
142,298
142,519
130,225
123,841
110,348
115,419
116,284
153,641
146,632
142,036
144,188
150,056
145,947
152,792
151,933
207,315
201,232
201,232207,315151,933152,792145,947150,056144,188142,036146,632153,641116,284115,419110,348123,841130,225142,519142,298179,016156,005228,709232,170246,448162,369
   > Total Current Liabilities 
66,787
59,963
68,869
68,150
54,816
58,208
64,010
66,016
50,907
46,884
36,503
36,421
42,289
60,110
57,155
54,513
58,603
63,217
66,487
74,306
72,353
77,225
73,114
73,11477,22572,35374,30666,48763,21758,60354,51357,15560,11042,28936,42136,50346,88450,90766,01664,01058,20854,81668,15068,86959,96366,787
       Accounts payable 
6,624
5,843
10,394
6,339
5,158
6,408
8,910
4,415
3,402
5,050
4,693
6,169
6,836
9,511
9,047
8,066
10,411
8,269
7,966
13,769
12,491
5,493
5,465
5,4655,49312,49113,7697,9668,26910,4118,0669,0479,5116,8366,1694,6935,0503,4024,4158,9106,4085,1586,33910,3945,8436,624
       Other Current Liabilities 
1,558
35,012
44,157
45,780
23,009
21,714
33,117
34,000
22,705
11,333
5,817
0
4,221
8,221
0
8,221
8,221
0
0
0
0
0
0
0000008,2218,22108,2214,22105,81711,33322,70534,00033,11721,71423,00945,78044,15735,0121,558
   > Long-term Liabilities 
95,582
186,485
163,301
160,559
101,189
120,808
78,288
76,503
79,318
76,957
73,845
78,998
73,995
93,531
89,477
87,523
60,667
86,839
79,460
78,486
79,580
130,090
128,118
128,118130,09079,58078,48679,46086,83960,66787,52389,47793,53173,99578,99873,84576,95779,31876,50378,288120,808101,189160,559163,301186,48595,582
       Capital Lease Obligations Min Short Term Debt
17,650
29,081
27,179
28,803
26,710
26,135
28,885
30,256
28,693
26,378
23,163
20,257
21,301
43,946
37,137
37,186
34,611
36,536
34,139
38,698
38,488
35,032
31,133
31,13335,03238,48838,69834,13936,53634,61137,18637,13743,94621,30120,25723,16326,37828,69330,25628,88526,13526,71028,80327,17929,08117,650
       Other Liabilities 
82,380
163,208
141,771
138,406
80,821
101,484
56,667
55,221
60,888
60,888
60,888
68,888
64,667
60,667
0
60,667
60,667
0
0
0
0
0
0
00000060,66760,667060,66764,66768,88860,88860,88860,88855,22156,667101,48480,821138,406141,771163,20882,380
> Total Stockholder Equity
209,990
262,437
234,567
426,772
441,152
393,586
637,996
613,361
586,794
553,642
512,760
465,414
414,745
360,680
317,473
399,917
360,462
349,097
294,400
232,009
175,634
134,274
62,420
62,420134,274175,634232,009294,400349,097360,462399,917317,473360,680414,745465,414512,760553,642586,794613,361637,996393,586441,152426,772234,567262,437209,990
   Common Stock
5
5
5
6
6
6
7
7
7
7
7
7
7
7
0
8
8
0
0
0
0
0
0
00000088077777777666555
   Retained Earnings Total Equity00000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
39
107
694
183
-48
-46
-73
-71
-64
-493
-2,509
-3,387
-4,291
-3,601
0
-2,285
-1,452
0
0
0
0
0
0
000000-1,452-2,2850-3,601-4,291-3,387-2,509-493-64-71-73-46-4818369410739



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue32,314
Cost of Revenue--
Gross Profit-32,314
 
Operating Income (+$)
Gross Profit-
Operating Expense-271,234
Operating Income-238,920-271,234
 
Operating Expense (+$)
Research Development199,247
Selling General Administrative71,987
Selling And Marketing Expenses-
Operating Expense271,234271,234
 
Net Interest Income (+$)
Interest Income14,062
Interest Expense--
Other Finance Cost-0
Net Interest Income14,062
 
Pretax Income (+$)
Operating Income-238,920
Net Interest Income14,062
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-237,093-226,685
EBIT - interestExpense = 0
-237,093
-237,093
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--237,093
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-237,093
Tax Provision--
Net Income From Continuing Ops-237,093-237,093
Net Income-237,093
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-12,235-14,062
 

Technical Analysis of Editas Medicine Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Editas Medicine Inc. The general trend of Editas Medicine Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Editas Medicine Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Editas Medicine Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Editas Medicine Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.991 < 3.052 < 3.364.

The bearish price targets are: 2.019 > 1.7525 > 1.4065.

Know someone who trades $8EM? Share this with them.πŸ‘‡

Editas Medicine Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Editas Medicine Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Editas Medicine Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Editas Medicine Inc.

Editas Medicine Inc Daily Moving Average Convergence/Divergence (MACD) ChartEditas Medicine Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Editas Medicine Inc. The current adx is .

Editas Medicine Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Editas Medicine Inc.

Editas Medicine Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Editas Medicine Inc.

Editas Medicine Inc Daily Relative Strength Index (RSI) ChartEditas Medicine Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Editas Medicine Inc.

Editas Medicine Inc Daily Stochastic Oscillator ChartEditas Medicine Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Editas Medicine Inc.

Editas Medicine Inc Daily Commodity Channel Index (CCI) ChartEditas Medicine Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Editas Medicine Inc.

Editas Medicine Inc Daily Chande Momentum Oscillator (CMO) ChartEditas Medicine Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Editas Medicine Inc.

Editas Medicine Inc Daily Williams %R ChartEditas Medicine Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Editas Medicine Inc.

Editas Medicine Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Editas Medicine Inc.

Editas Medicine Inc Daily Average True Range (ATR) ChartEditas Medicine Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Editas Medicine Inc.

Editas Medicine Inc Daily On-Balance Volume (OBV) ChartEditas Medicine Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Editas Medicine Inc.

Editas Medicine Inc Daily Money Flow Index (MFI) ChartEditas Medicine Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Editas Medicine Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-06 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-07 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-12 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-13 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-10 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-22 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-09 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-16 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-21 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-22 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-27 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-18 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-26 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-27 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-30 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-01 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-03 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Editas Medicine Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Editas Medicine Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.544
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Editas Medicine Inc with someone you think should read this too:
  • Are you bullish or bearish on Editas Medicine Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Editas Medicine Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Editas Medicine Inc

I send you an email if I find something interesting about Editas Medicine Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Editas Medicine Inc.

Receive notifications about Editas Medicine Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.